{"id":"NCT00717236","sponsor":"UCB Pharma","briefTitle":"Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis","officialTitle":"A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2010-03","completion":"2011-03","firstPosted":"2008-07-17","resultsPosted":"2011-05-06","lastUpdate":"2018-08-01"},"enrollment":1648,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Certolizumab pegol (CZP)","otherNames":["Cimzia"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Certolizumab pegol (CZP)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.","primaryOutcome":{"measure":"American College of Rheumatology 20% (ACR20) Response at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Certolizumab Pegol (CZP)","deltaMin":51.1,"sd":null},{"arm":"Placebo","deltaMin":25.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":181,"countries":["United States","Canada","France","Germany","Italy","Netherlands","Spain"]},"refs":{"pmids":["26614481","26568428","22923753"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":846},"commonTop":["Upper respiratory tract infection","Rheumatoid Arthritis","Urinary Tract Infection","Headache","Nasopharyngitis"]}}